Pro MedicusASX:PME +1.88%98 FCF Yield % is 0.61 as of Jun. 27, 2026, which is 5% below its 10-year median of 0.64. GuruFocus rates ASX:PME with a GF Score™ of 98/100 and a GF Value™ of A$245.06 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 687 Healthcare Providers & Services companies, Pro Medicus ranks worse than 55.46% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Pro Medicus's FCF Yield % or its related term are showing as below:
ASX:PME'
s FCF Yield % Range Over the Past 10 Years
Min: 0.05 Med: 0.64 Max: 1.7
Current: 0.61
During the past 13 years, the highest FCF Yield % of Pro Medicus was 1.70%. The lowest was 0.05%. And the median was 0.64%.
ASX:PME's FCF Yield % is ranked worse than 55.46% of 687
companies
in the Healthcare Providers & Services industry
Industry Median: 1.91
vs ASX:PME: 0.61
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Pro Medicus FCF Yield % Related Terms
Pro Medicus FCF Yield % Historical Data
* Premium members only.
The historical data trend for Pro Medicus's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PME vs VEEV, BTSG, TEM: FCF Yield % Comparison
For the Health Information Services subindustry, Pro Medicus's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus FCF Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Pro Medicus's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro Medicus (ASX:PME) has a FCF Yield % of 0.61 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Pro Medicus and its competitors. This is near median its historical median of 0.64. Over the past decade, Pro Medicus' FCF Yield % has ranged from 0.05 to 1.70. According to the industry distribution chart, Pro Medicus ranks #381 out of 687 companies in the Healthcare Providers & Services industry, placing it in the top 55.5%.
Is Pro Medicus' FCF Yield % too high?
Pro Medicus' current FCF Yield % of 0.61 is near median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 1.70. The Healthcare Providers & Services industry median FCF Yield % is 1.91. Pro Medicus' value of 0.61 is 68.1% below this industry median. Based on the distribution chart, Pro Medicus ranks #381 out of 687 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Pro Medicus has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' FCF Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Pro Medicus ranks #381 out of 687 companies for FCF Yield %. This places Pro Medicus in the lower half of its industry. The industry median FCF Yield % is 1.91. Pro Medicus' value of 0.61 is 68.1% below this benchmark. Historically, Pro Medicus' own FCF Yield % has ranged from 0.05 to 1.70 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 1.91, Pro Medicus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Healthcare Providers & Services company?
The median FCF Yield % among Healthcare Providers & Services companies is 1.91, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current FCF Yield % of 0.61 is 68.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Pro Medicus and its competitors. For the Healthcare Providers & Services industry, the median FCF Yield % is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current FCF Yield % is 0.61, which is near median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$245.06, compared to a current price of A$188.88 — trading 22.9% below its estimated fair value. The current FCF Yield % is 0.61, which is near median its 10-year median of 0.64 and 68.1% below the Healthcare Providers & Services industry median of 1.91. Pro Medicus' overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current FCF Yield % is 0.61 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (ASX:PME) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of A$188.88 is trading 22.9% below its estimated GF Value™ of A$245.06.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for ASX:PME:
FCF Yield %: 0.61 (near median its 10-year median of 0.64)
GF Value™: A$245.06 vs. price of A$188.88 (22.9% below fair value)
Industry Position: 68.1% below the Healthcare Providers & Services median (#381 of 687)
No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
98GF Score
Get the complete analysis for ASX:PME
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PME has been successfully added to your 
